Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines

Vaccine

Volumn 22, Issue 20, 2004, Pages 2626-2630

  Evans, Thomas G ^a,g   Frey, Sharon ^b   Israel, Heidi ^b   Chiu, Joseph ^c   El Habib, Raphaelle ^d   Gilbert, Peter ^e   Gaitan, Alicia ^f   Montefiori, David C ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d SANOFI PASTEUR   (France)

^e Fred Hutchinson Cancer Research Center   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g VICAL INC   (United States)

Author keywords

Antibodies; HIV 1; Vaccines

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CANARYPOX VIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERM MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS STRAIN; VOLUNTEER;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; B-LYMPHOCYTES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; VACCINES, SYNTHETIC;

EID: 2942595905     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.12.011     Document Type: Article

References (26)

1. Letvin N.L., Barouch D.H., Montefiori D.C. Prospects for vaccine protection against HIV-1 infection and AIDS. Ann. Rev. Immunol. 20:2002;73-99
2. Foresman L., Jia F., Li Z., Wang C., Stephens E.B., Sahni M., et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res. Hum. Retroviruses. 14:1998;1035-1043
3. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:1999;204-210
4. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:1999;4009-4018
5. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2000;207-210
6. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200-206
7. Parren W.H.I., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Meyer C., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:2001;8340-8347
8. Montefiori D.C., Altfeld M., Lee P.K., Bilska M., Zhou J.T., Gao F., et al. Viremia control despite escape from a rapid and potent neutralizing antibody response after treatment-cessation in an HIV-1-infected individual. J. Immunol. 170:2003;3906-3914
9. Haigwood N.L., Watson A., Sutton W.F., McClure J., Lewis A., Ranchalis J., et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:1996;107-114
10. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1998;1884-1888
11. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1a. J. Infect. Dis. 173:1996;340-348
12. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K., Tartaglia J., et al. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 16:2000;2019-2035
13. Beddows S., Lister S., Cheingsong R., Bruck C., Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73:1999;1740-1745
14. Belshe R.B., Gorse G.J., Mulligan M.J., Evans T.G., Keefer M.C., Excler J.-L., et al. Induction of immune responses to HIV-1 canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS. 12:1998;2407-2415
15. Evans T.G., Keefer M.C., Weinhold K., Wolff M., Montefiori D.C., Gorse G.J., et al. A canarypox vaccine expressing multiple HIV-1 genes given alone or with SF-2 rgp120 elicits broad and durable CTL responses in seronegative volunteers. J. Infect. Dis. 180:1999;290-298
16. Gupta K., Hudgens M., Corey L., McElrath M.J., Weinhold K., Montefiori D.C., et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J. Acquir. Immune Defic. Syndr. 29:2002;254-261
17. Belshe R.B., Stevens C., Gorse G.J., Buchbinder S., Weinhold K., Sheppard H., et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 183:2001;1343-1352
18. Keefer M.C., Wolff M., Gorse G.J., Graham B.S., Corey L., Clements-Mann M.L., et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses. 13:1997;1163-1177
19. Montefiori D.C., Robinson W.E. Jr., Schuffman S.S., Mitchell W.M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:1988;231-235
20. Cheng-Mayer C., Homsy J., Evans L.A., Levy J.A. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc. Natl. Acad. Sci. U.S.A. 85:1988;2815-2819
21. Louwagie J., Delwart E.L., Mullins J.I., McCutchan F.E., Eddy G., Burke D.S. Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes. AIDS Res. Hum. Retroviruses. 10:1994;561-567
22. Crawford J.M., Earl P.L., Moss B., Reimann K.A., Wyand M.S., Manson K.H., et al. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J. Virol. 73:1999;10199-10207
23. Graham B.S., Keefer M.C., McElrath M.J., Gorse G.J., Schwartz D.H., Weinhold K., et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial, NIAID AIDS Vaccine Evaluation Group. Ann. Intern. Med. 125:1996;270-279
24. McElrath M.J., Corey L., Montefiori D., Wolff M., Schwartz D., Keefer M., et al. A phase II study of two HIV type 1 envelope vaccines% comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses. 16:2000;907-919
25. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17:1999;1075-1081
26. Montefiori D.C., Evans T.G. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res. Hum. Retroviruses. 15:1999;689-698